التفاصيل البيبلوغرافية
| العنوان: |
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with orWithout the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. |
| المؤلفون: |
Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L. |
| المصدر: |
Oncologist; Mar2017, Vol. 22 Issue 3, p264-271, 8p, 1 Diagram, 4 Charts, 2 Graphs |
| مصطلحات موضوعية: |
ANTINEOPLASTIC agents, BIOMARKERS, COLON tumors, CONFIDENCE intervals, FLUOROURACIL, FOLINIC acid, IMMUNOHISTOCHEMISTRY, METASTASIS, MONOCLONAL antibodies, ORGANOPLATINUM compounds, PATIENT safety, RECTUM tumors, RESEARCH funding, STATISTICAL sampling, SURVIVAL, VASCULAR endothelial growth factors, OXALIPLATIN, RANDOMIZED controlled trials, TREATMENT effectiveness, BEVACIZUMAB, PROPORTIONAL hazards models, BLIND experiment, DISEASE progression |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Background. Dysregulated hepatocyte growth factor/mesenchymal-epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double-blind, multicenter phase II trial of the MET inhibitor onartuzumab in combination with mFOLFOX-6 and bevacizumab for mCRC (GO27827; NCT01418222). Materials and Methods. Patients were randomized 1:1 to receive onartuzumab (10 mg/kg intravenously [IV]) or placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV). Oxaliplatin was given for 8-12 cycles; other agents were continued until disease progression, unacceptable toxicity, or death. The primary endpoint was progression-free survival (PFS) in the intent-to-treat (ITT) and MET immunohistochemistry (IHC) expression-positive populations. Results. Between September 2011 and November 2012, 194 patients were enrolled. In September 2013, an interim analysis recommended stopping onartuzumab treatment due to lack of efficacy. At the time of the final analysis in February 2014, no significant improvement in PFS was seen with onartuzumab versus placebo in either the ITT or MET IHC-positive populations. An improvement in PFS was noted in the MET IHC-negative population. Neither overall survival nor response rate was improved with onartuzumab. The incidence of fatigue, peripheral edema, and deep vein thrombosis was increased with onartuzumab relative to placebo. Conclusion. Onartuzumab combined with mFOLFOX-6 and bevacizumab did not significantly improve efficacy outcomes in either the ITT or MET IHC-positive populations. MET expression by IHC was not a predictive biomarker in this setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
